What Is GSK plc (GSK) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, GSK plc's intrinsic value is estimated at $41.55, suggesting the stock is overvalued at its current price of $51.25. With 9 out of 12 models flagging downside (-18.9% average return), the market may be pricing in unsustainable growth. Notably, RCMH-DCF sees the most upside at +31.6% (fair value: $67.47), while Markov DDM is the most conservative at -62.5% ($19.20). The spread between these extremes — +94.2% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About GSK?
12 of 13 models are currently active for GSK. Of these, 3 models suggest upside while 9 models suggest overvaluation. The Bayesian DCF estimates GSK's intrinsic value at $42.65, implying -16.8% downside from the current price. See which stocks rank higher →
How Does GSK Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, GSK ranks #36 by Quality of Company score. CirclFi's QOC score of 8.0/10 evaluates 32 fundamental signals. A score of 8.0 places GSK in the top tier.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, GSK plc competes in an environment where FDA approval probability often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is GSK a Value Trap?
CirclFi's Value Trap algorithm assigns GSK a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for GSK plc. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, GSK plc's fundamental quality profile registers 8.0/10. This robust score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +94.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every GSK valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across GSK's 12 active models, average confidence is 42%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad